Novo Nordisk A/S

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Novo Nordisk stock weighs outlook boost against pricing pressure

Drug pricing Earnings report Guidance raised AI-generated analysis

πŸ“ˆ Novo Nordisk raised its 2026 adjusted sales and operating profit outlook to a range of minus 2% to plus 2% at constant exchange rates, improving from a previous forecast of a 6% decline.

πŸ’° Third-quarter sales increased 4% at constant exchange rates to DKK 79.2 billion, beating FactSet expectations of DKK 73.6 billion.

πŸš€ Adjusted operating profit jumped 27% to DKK 31.7 billion in the third quarter, significantly above the expected DKK 28.6 billion.

πŸ’Š Wegovy pill sales totaled DKK 5.4 billion in Q3, exceeding analyst estimates of roughly DKK 4.5 billion due to strong demand.

🌍 The company expects its oral Wegovy treatment to reach more than 20 markets by the first half of 2027 after launching in eight markets by early November.

⚠️ Management warns that pricing pressure and intensifying competition, especially from Eli Lilly in the U.S., remain key risks to future performance.

πŸ“‰ CEO Mike Doustdar cautioned that one strong quarter is not enough to establish a full turnaround as investors focus on prescription growth durability.

πŸ‡ΊπŸ‡Έ The outlook assumes continued international growth but anticipates declining U.S. sales due to competitive pressure and lower realized prices.

πŸ₯ Novo Nordisk maintains an 80% share of the oral obesity market in the United States for its Wegovy product.

Bullish Signals
  • Novo Nordisk raised its 2026 adjusted sales and operating profit outlook to a range of minus 2% to plus 2% at constant exchange rates, a significant improvement from the previous forecast of a 6% decline to flat growth.
  • Third-quarter sales rose 4% at constant exchange rates to DKK 79.2 billion, beating analyst expectations of DKK 73.6 billion driven by strong GLP-1 demand.
  • Adjusted operating profit increased 27% to DKK 31.7 billion in the third quarter, surpassing the expected DKK 28.6 billion and demonstrating improved profitability.
  • Wegovy pill sales reached DKK 5.4 billion in Q3, exceeding analyst estimates of roughly DKK 4.5 billion, indicating robust recovery in oral medication demand.
  • The company successfully expanded its oral treatment availability to eight markets by early November with a plan to reach over 20 markets by the first half of 2027.
Risk Factors
  • Pricing pressure linked to market-access investments and competitive dynamics are expected to weigh on U.S. sales, leading to anticipated declines in that region.
  • Intensifying competition from Eli Lilly's obesity portfolio has gained ground in the United States, posing a direct threat to Novo Nordisk's market share and pricing power.
  • CEO Mike Doustdar cautioned that a single strong quarter is insufficient to establish a full turnaround, leaving uncertainty about the durability of prescription growth.
  • The revised outlook assumes declining U.S. sales despite continued international growth, highlighting a specific regional weakness in the company's revenue mix.
Full Analysis
Novo Nordisk has revised its full-year 2026 outlook upward, adjusting expectations for adjusted sales and operating profit to a range of minus 2% to plus 2% at constant exchange rates. This represents a significant improvement from the previous forecast of a 6% decline to flat growth, driven primarily by stronger-than-anticipated demand for its oral GLP-1 medication, Wegovy. Third-quarter financial results exceeded analyst expectations, with sales rising 4% at constant exchange rates to DKK 79.2 billion and adjusted operating profit surging 27% to DKK 31.7 billion. Specifically, Wegovy pill sales reached DKK 5.4 billion in the quarter, surpassing consensus estimates of roughly DKK 4.5 billion, while injectable Wegovy and Ozempic generated DKK 20.4 billion and DKK 29.7 billion respectively. Despite the positive earnings beat and outlook revision, management highlights persistent headwinds including pricing pressure from market-access investments and intensifying competition, particularly from Eli Lilly in the United States. CEO Mike Doustdar noted that while Wegovy holds an 80% share of the U.S. oral obesity market, a single strong quarter is insufficient to confirm a full turnaround as investors scrutinize the durability of prescription growth amidst these competitive challenges. Looking ahead, the company plans to expand the availability of its Wegovy pill to more than 20 markets by the first half of 2027, having already launched in eight markets by early November. The outlook assumes continued international expansion but anticipates declining U.S. sales due to the aforementioned competitive and pricing dynamics, creating a mixed sentiment for the stock as it weighs growth potential against margin pressures.